Pay in 4 interest-free payments of $5.29 Learn more
Ships within 48 hours · Estimated delivery Aug 16 - Aug 21
It's no surprise that the biopharma industry is racing to capture a share of that growth as GLP-1 use accelerates
Tirzepatide: The Double-Barrel GLP-1 and GIP Agonist Tirzepatide (sold under brand names like Mounjaro and Zepbound ) is a dual-action peptide that activates both GLP-1 and GIP receptors
Hsia DS, Grove O, Cefalu WT
Safety in TRIUMPH-1 The safety profile was consistent with incretin-class therapies: Most common AEs (12 mg dose): - Nausea: 42.4% - Diarrhea: 32.0% - Constipation: 26.1% - Vomiting: 25.3% Dysesthesia (a sensory disturbance tingling, numbness) and urinary tract infections were reported in approximately 10% of patients on the highest doses, but were generally mild to moderate and mostly resolved during treatment
